Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Core Viewpoint - The proposed sale of Astria Therapeutics, Inc. to BioCryst Pharmaceuticals, Inc. is under investigation to assess whether the offered consideration adequately values Astria [1] Group 1: Transaction Details - Shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria they own [1] - The law firm Kahn Swick & Foti, LLC is investigating the adequacy of this consideration and the process leading to the proposed sale [1] Group 2: Legal Rights and Contact Information - Individuals who believe the transaction undervalues Astria can contact KSF Managing Partner Lewis S. Kahn for discussions regarding their legal rights [2] - KSF offers a no-obligation consultation for those interested in the proposed sale [2]